Ascelia Pharma
13.88 SEK -0.14%HC Andersen Capital receives payment from Ascelia Pharma for a DigitalIR/Corporate Visibility agreement. See disclaimer.
Ascelia Pharma is a Swedish biotech company with a focus on orphan oncology treatments. They develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. Currently, Ascelia pharma has two pipeline products, namely Orviglance and Oncoral. Orviglance is a novel contrast agent for MR-Imaging developed to improve the detecting and visualization of focal liver lesions (Including liver metastases – and primary tumors) in patients with reduced kidney function. Oncoral is a daily tablet with an established potent anti-tumor effect – even in difficult to treat cancers with the potential to offer better patient outcomes with improved safety following a daily tablet treatment compared to intravenous high-dose infusions at the hospital. Ascelia Pharma is listed on Nasdaq Small Cap Stockholm with ticker ACE.
Read moreLatest research
Analyst
Latest videos
Financial calendar
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Sunstone life Science Ventures Fund II K/S | 13.7 % | 14.1 % |
Avanza Pension | 8.2 % | 8.4 % |
Premium
This content is for our Premium customers only.
Ascelia Pharma utnyttjar den andra tranchen om 15 MSEK under befintlig lånefacilitet
Ascelia Pharma rapporterar att SPARKLE-bildläsningsfasen är avslutad och förväntar sig headline-resultat i första halvan av maj 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits